We are always excited to showcase innovative publications utilizing our reagents. We take immense pride in providing researchers and professionals with reliable and consistent products that unlock new possibilities in their fields. Today, we delve into another new study using some of of our primary human brain cells.
Researchers from the University of Nottingham have released two new publications using our primary human brain microvascular endothelial cells (cat. HEC02), brain pericytes (cat. HMP104), and brain astrocytes (cat. HMP202) to build an in vitro blood-brain barrier (BBB) model. Last week, we highlighted the first publication, where the impact of exposure to Substance P (SP) on the BBB was evaluated. You can check out the blog post to learn more.
Image: Astrocytes stained with S100 beta.
Then, to our pleasant surprise, we saw the researchers cited our cells in another BBB related publication. This time, the investigators looked into some of the mechanisms behind neuroinflammation seen in ischaemic stroke and other disorders. They found that inhibition of Rho kinase neutralized the disruptive effects of TNF-α on BBB integrity. You can read the full study here.
Along with our human cells, we have the culturing tools to keep them happy and healthy throughout the entirety of your experiment. This includes fetal bovine serum (FBS), cell-specific growth media, coating solutions, detachment solutions, and more. A customer just mentioned to us that our endothelial cells demonstrate "increased resistance and avoid both senescence and apoptosis induced by oxysterols" when using our ENDO-Growth Media (cat. MED001) in comparison to competitor formulations.